Exscientia plc: Data Presented at AACR 2023 Highlights Exscientia's Clinical and Preclinical Development
Includes recent advancements from precision designed compounds Functional personalised medicine platform unveiling unique adenosine biomarker to enrich for patients more likely to respond to treatment